| Literature DB >> 26681261 |
Chiara Simone1, Agnese Ramirez1, Monica Bucchia1, Paola Rinchetti1, Hardy Rideout2, Dimitra Papadimitriou2, Diane B Re3,4, Stefania Corti5.
Abstract
Spinal muscular atrophy (SMA) is a genetic neurological disease that causes infant mortality; no effective therapies are currently available. SMA is due to homozygous mutations and/or deletions in the survival motor neuron 1 gene and subsequent reduction of the SMN protein, leading to the death of motor neurons. However, there is increasing evidence that in addition to motor neurons, other cell types are contributing to SMA pathology. In this review, we will discuss the involvement of non-motor neuronal cells, located both inside and outside the central nervous system, in disease onset and progression. Even if SMN restoration in motor neurons is needed, it has been shown that optimal phenotypic amelioration in animal models of SMA requires a more widespread SMN correction. It has been demonstrated that non-motor neuronal cells are also involved in disease pathogenesis and could have important therapeutic implications. For these reasons it will be crucial to take this evidence into account for the clinical translation of the novel therapeutic approaches.Entities:
Keywords: Central nervous system; Pathogenesis; Spinal muscular atrophy; Therapy
Mesh:
Year: 2015 PMID: 26681261 PMCID: PMC4756905 DOI: 10.1007/s00018-015-2106-9
Source DB: PubMed Journal: Cell Mol Life Sci ISSN: 1420-682X Impact factor: 9.261